Loading organizations...
Biopharmaceutical Research Company is a Castroville, California-based enterprise that cultivates federally compliant cannabis and extracts active pharmaceutical ingredients for plant-based therapeutics. The organization supplies standardized, research-grade botanical materials and comprehensive analytical testing services to major academic institutions, biotechnology firms, and pharmaceutical developers conducting clinical trials. By securing a specialized registration from the United States Drug Enforcement Administration in 2021, the business became one of the first domestic entities authorized to legally produce cannabis specifically for federal research purposes. To expand its cultivation operations and scientific capabilities, the company closed a $20 million Series A funding round in April 2022. This financing was supported by institutional venture capital investors, featuring recognizable financial backers such as Luzich Partners and AFI Capital Partners. Biopharmaceutical Research Company was founded in 2017 by former United States Navy SEAL George Hodgin.
Biopharmaceutical Research Company has raised $20.0M across 1 funding round.
Biopharmaceutical Research Company has raised $20.0M in total across 1 funding round.
Biopharmaceutical Research Company has raised $20.0M across 1 funding round. Most recently, it raised $20.0M Series A in October 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 4, 2022 | $20M Series A | Howard Goodwin | Achari Ventures, AFI Capital Partners, Argonautic Ventures, Delta Emerald Ventures, Self Health America | Announced |
Biopharmaceutical Research Company has raised $20.0M in total across 1 funding round.
Biopharmaceutical Research Company's investors include Howard Goodwin, Achari Ventures, AFI Capital Partners, Argonautic Ventures, Delta Emerald Ventures, Self Health America.
